Filtered By:
Condition: Pain
Infectious Disease: COVID-19
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 154 results found since Jan 2013.
Stroke and presence of patent foramen ovale in sickle cell disease
AbstractSickle cell disease (SCD) is an inherited monogenic hemoglobinopathy characterized by formation of sickle erythrocytes under conditions of deoxygenation. Sickle erythrocytes can lead to thrombus formation and vaso-occlusive episodes that may result in hemolytic anemia, pain crisis and multiple organ damage. Moreover, SCD is characterized by endothelial damage, increased inflammatory response, platelet activation and aggravation, and activation of both the intrinsic and the extrinsic coagulation pathways. Cerebrovascular events constitute an important clinical complication of SCD. Children with SCD have a 300-fold h...
Source: Journal of Thrombosis and Thrombolysis - February 26, 2021 Category: Hematology Source Type: research
Study Documents Neurological, Psychiatric Complications From COVID-19
While previous studies and case reports have found that COVID-19 patients have experienced vascular and neurological problems, a newstudy inthe Lancet Psychiatry reports that patients are also showing symptoms of psychiatric disorders, including psychosis and depression.The study was the result of a collaborative effort of specialists in the United Kingdom to document COVID-19 complications.“To our knowledge, this is the first systematic, nationwide U.K. surveillance study of the breadth of acute complications of COVID-19 in the nervous system,” wrote Aravinthan Varatharaj, M.R.C.P., of University Hospital Southampton ...
Source: Psychiatr News - June 29, 2020 Category: Psychiatry Tags: Aravinthan Varatharaj brain hemorrhage brain inflammation cognition COVID-19 depression Lancet Psychiatry pain psychiatric disorders psychosis stroke United Kingdom weakness Source Type: research
Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series
Curr Neurovasc Res. 2021 Sep 26. doi: 10.2174/1567202618666210927095613. Online ahead of print.ABSTRACTCoronavirus disease-19 (COVID-19) is an infectious disease with high morbidity and mortality rates. Indonesia had reported a 2.8% of mortality rate up to June 2021. A strategy to control the virus spreading is by vaccination. The Indonesian Food and Drug Monitoring Agency had approved the use of CoronaVac, an inactivated virus vaccine developed by Sinovac. Most adverse events following immunization (AEFI) for CoronaVac are mild, and the most common symptoms are injection-site pain, headache, and fatigue. Neurovascular adv...
Source: Current Neurovascular Research - September 28, 2021 Category: Neurology Authors: Rakhmad Hidayat Dinda Diafiri Ramdinal Aviesena Zairinal Ghafur Rasyid Arifin Faiza Azzahroh Nita Widjaya Devi Nurfadila Fani Taufik Mesiano Mohammad Kurniawan None Al Rasyid Astuti Giantini Salim Haris Source Type: research
SNMMI 2020: PET radiotracer measures stroke recovery
A new PET radiotracer may one day help clinicians evaluate stroke recovery,...Read more on AuntMinnie.comRelated Reading:
SNMMI 2020: PET/MRI finds location of chronic pain in patients
SNMMI 2020: How nuclear medicine handled COVID-19
SNMMI 2020: Radionuclide treatment paves way for immunotherapy
SNMMI 2020: Medical students key to the specialty's future
Digital FDG-PET offers insights into hearing loss
Source: AuntMinnie.com Headlines - July 15, 2020 Category: Radiology Source Type: news
Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine
We describe the first Danish case of presumed inflammatory and thrombotic response to vaccination with an adenoviral (ChAdOx1) vector based COVID-19 vaccine (AZD1222). The case describes a 60-year old woman, who was admitted with intractable abdominal pain seven days after receiving the vaccine. Computer Tomography (CT) of the abdomen revealed bilateral adrenal hemorrhages. On the following day she developed a massive right sided ischemic stroke and Magnetic Resonance Imaging (MRI) angiography showed occlusion of the right internal carotid artery. The ischemic area was deemed too large to offer reperfusion therapy. During ...
Source: Thrombosis and Haemostasis - April 20, 2021 Category: Hematology Authors: Rolf Ankerlund Blauenfeldt S øren Risom Kristensen Siw Leiknes Ernstsen Claudia Christina Hilt Kristensen Claus Ziegler Simonsen Anne-Mette Hvas Source Type: research
COVID-19 Has Numerous Neuropsychiatric Consequences, Report Finds
Anarticle appearing today in theJournal of Neuropsychiatry and Clinical Neurosciences provides a comprehensive overview of the neurological and psychiatric impact of the COVID-19 pandemic.“Although best known for its severe effects on respiratory function, SARS-CoV-2 produces a broad range of acute and chronic neurological and neuropsychiatric problems,” wrote Theodora Manolis, M.D., of Red Cross Hospital in Athens, Greece, and colleagues. “The COVID-19 pandemic has also had an important impact on the mental health of many individuals in the general population as a result of loss of loved ones, fear of calamity or de...
Source: Psychiatr News - July 20, 2021 Category: Psychiatry Tags: COVID-19 delirium depression headache hypoxia Journal of Neuropsychiatry and Clinical Neurosciences muscle pain neurological problems psychiatric problems psychosis stroke Source Type: research
Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series
We report 8 patients with focal neurological symptoms after receiving inactivated virus vaccine, CoronaVac.Case seriesPatients were aged 24 –48 years and 75% were female. Acute onset of focal neurological symptoms occurred within the first 24 h after vaccination in 75% and between 1-7d in 25%. All presented with lateralized sensory deficits, motor deficits, or both, of 2–14 day duration. Migraine headache occurred in half of t he patients. Magnetic resonance imaging of the brain during and after the attacks did not demonstrate any abnormalities suggesting ischemic stroke. All patients showed moderately large regi...
Source: The Journal of Headache and Pain - January 21, 2022 Category: Neurology Source Type: research
Chronic cerebral aspects of long COVID, post ‐stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic
This article is about how the neurological aspects of long COVID (fatigue, neurogenic pain, loss of ability to taste or smell), can be best understood, and treated. For this purpose, the literature on TNF and brain function, both physiological and disease-associated, and how this is being applied to various long-term neurodegenerative conditions, is discussed. AbstractThe chronic neurological aspects of traumatic brain injury, post-stroke syndromes, long COVID-19, persistent Lyme disease, and influenza encephalopathy having close pathophysiological parallels that warrant being investigated in an integrated manner. A mechan...
Source: Pharmacology Research and Perspectives - February 17, 2022 Category: Drugs & Pharmacology Authors: Ian Albert Clark Tags: REVIEW ARTICLE Source Type: research
How John Fetterman Came Out of the Darkness
When he looks back on the past year—a year in which he nearly died, became a U.S. Senator, and nearly died again—it is the debate that John Fetterman identifies as the breaking point.
“The debate lit the mitch,” he says, then shakes his head in frustration and tries again. The right word is there in his brain, but he struggles to get it out. “Excuse me, that should be lit the mitch—” He stops and tries again. “Lit the match,” he says finally.
Oct. 25, 2022: the date is lodged in his mind. “I knew I had to do it,” he tells me. “I knew that the vote...
Source: TIME: Health - July 20, 2023 Category: Consumer Health News Authors: Molly Ball Tags: Uncategorized Congress Cover Story Exclusive feature uspoliticspolicy Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
